Synaptic, Ciba-Geigy Ltd. deal

The companies extended their agreement to develop therapies for obesity and eating disorders. Although SNAP did not disclose the extended term of the agreement, the original three-year pact was to lapse in August 1997. The new agreement allows for additional research on undisclosed targets to treat obesity.

The research has focused on the development of small molecules that act on Neuropeptide Y receptors. NPY, a peptidic neurotransmitter, is a potent feeding stimulator. ...